Brazil Axial Spondyloarthritis (axSpA) Market Analysis

The Brazil Axial Spondyloarthritis (axSpA) Market stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Brazil Axial Spondyloarthritis (axSpA) Market Analysis Executive Summary

Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disease that predominantly involves the spine and sacro-iliac joints but can affect other joints and structures, including internal organs. It is a chronic condition that may be hereditary, developing between 20 and 40 years of age. There are two types: For example, the categories are radiographic axial spondyloarthritis (radiographic axSpA), where the individual has joint inflammation using X-ray evidence of sacroiliac joint structural change, and nonradiographic axSpA (nr-axSpA), where the patient may have sacroiliac joint inflammation but minimal or no structural changes using X-rays. AS is slightly prevalent in men than in women while nr-axSpA affects both sexes with equal prevalence. It has been identified that the disease is not as prevalent among African Americans as it is among other races. The estimated incidence of axial spondyloarthritis (axSpA) across the globe is believed to be between 0.3 to 1.4%. Conventional management for axial spondyloarthritis (axSpA) involves NSAIDs as an initial approach to managing pain associated with the condition. Others may prescribe physical therapy, exercise, and in some cases, the use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) such as sulfasalazine.

Axial spondyloarthritis (axSpA) market is the most promising as the disease incidence grows, primarily in North America and the European markets. Currently, North America and Europe dominate the market, while Asia Pacific is growing faster due to better healthcare coverage and growth needs. Among threats there is a problem of timely diagnosis, high cost, and side effects of treatment but there is an opportunity to develop biosimilars, prescriptive medicines, and collaborate with the industry which will contribute to the growth of the market.    

Brazil Axial Spondyloarthritis (axSpA) Market Dynamics

Market Growth Drivers

The global axial spondyloarthritis (axSpA) market is expected to exhibit robust growth in the future mainly due to increasing incidence rate for the disease in developing as well as developed countries of North America and Europe because of better diagnosis, growing awareness about the disease, increasing aging population, and adverse lifestyle changes. Other factors that drive the market growth are the availability of NSAIDs, biologics and other therapies, improvements in diagnostic capabilities and increased disease knowledge. The factors such as proper reimbursement policies and increasing healthcare expenditure in countries like the U.S also boost the market size. 

Opportunity

There is great opportunity to be found in the discovery of new treatments like biologics and small molecules that focus on inflammatory mechanisms. Additionally, personalized medicine approaches that use diagnostic tools and biomarkers to match patients with the most appropriate treatments are gaining traction. Biosimilar development to provide better access to patients and make them adhere to their treatment plan as well as enhancing disease awareness and early detection of the disease will also be instrumental in determining the direction of the market. 

Market Restraints

The axial spondyloarthritis (axSpA) Market has few key constraints, one of the most crucial of which is cost-related challenges, with respect to treatment for its patients, especially for biologic agent’s therapies. Lack of awareness among the health practitioners and the general population leads to delayed diagnosis which in turn reduces treatment uptake. In turn, it is imperative to acknowledge that the side effects of biologic treatments including infections and allergies might reduce the usage of these treatments. High prices are maintained because there are few available generics caused by strict patents and regulatory concerns hinder the approval of new treatments. These factors altogether negatively impact the market growth, and thus, it takes a lot of effort to enhance its access and popularity. 

Competitive Landscape Axial Spondyloarthritis (axSpA) Market in Brazil

Key Players

• AbbVie Inc.
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• UCB S.A.
• Amgen Inc.

Recent Developments

June 2024, UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024. Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated with BIMZELX showed sustained and consistent clinical and patient-reported outcomes up to two years.

May 2024, Lupin launches biosimilar Etanercept in Canada.

March 2024, BIMZELX® (bimekizumab) Now Approved for Adults with Active Psoriatic Arthritis and for Adults with Axial Spondyloarthritis.

February 2024, FDA Accepts sBLA For Bimekizumab-Bkzx in 3 New Spondyloarthritides Indications.

October 2023, FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases.

Merger and Acquisition

June 2004, UCB acquired Celltech, a UK-based biopharmaceutical company, for £1.5 billion. This acquisition bolstered UCB's presence in the axial spondyloarthritis (axSpA) market, as Celltech brought a robust pipeline of biologics targeting inflammatory diseases.

Healthcare Policies and Regulatory Landscape for Axial Spondyloarthritis (axSpA) Market in Brazil

Policy changes and Reimbursement scenario

The market for axSpA has been advanced by favourable reimbursement policies especially in North America where the U.S and Canada dominate. However, due to the COVID-19 pandemic, some regions have been able to sustain this coverage, while others have been constrained by budget cuts on reimbursement. Treatment costs have also been found to be high and this remains a major impediment to the treatment seeking behaviour particularly in regions with constrained health resources. Biosimilars represent the potential for lower costs and increased availability. Related to the point above, awareness and advocacy are crucial in influencing reimbursement policies and guaranteeing patients required therapies.